Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenny Yu

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
The British Journal of Dermatology|April 6, 2023
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposureMark G Lebwohl, Joseph F Merola, Katelyn Rowland, et al.
Journal of Cellular Biochemistry|August 2, 2007
Chromatin organization and nuclear microenvironments in cancer cellsShihua He, Katherine L Dunn, Paula S Espino, et al.
Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 15, 2023
Safety and immunogenicity of the live-attenuated varicella vaccine in pediatric solid organ transplant recipients: A systematic review and meta-analysisPierre-Philippe Piché-Renaud, Erika Yue Lee, Catherine Ji, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
Elife|April 10, 2014
Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cellsDorothy K Sojka, Beatrice Plougastel-Douglas, Liping Yang, et al.
Molecular Therapy. Nucleic Acids|January 16, 2025
Erratum: U1 Adaptor Oligonucleotides Targeting <i>BCL2</i> and <i>GRM1</i> Suppress Growth of Human Melanoma Xenografts <i>In Vivo</i>Rafal Goraczniak, Brian A Wall, Mark A Behlke, et al.
Molecular Therapy. Nucleic Acids|May 16, 2013
U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In VivoRafal Goraczniak, Brian A Wall, Mark A Behlke, et al.
ACS Synthetic Biology|November 18, 2025
CloneCoordinate: Open-Source Software for Collaborative DNA ConstructionEthan Jeon, Ziyang Shen, Santiago Christ, et al.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|September 5, 2020
Developing a pediatric ophthalmology telemedicine program in the COVID-19 crisisSaloni Kapoor, Amgad Eldib, Jamila Hiasat, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
The British Journal of Dermatology|April 6, 2023
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposureMark G Lebwohl, Joseph F Merola, Katelyn Rowland, et al.
Journal of Cellular Biochemistry|August 2, 2007
Chromatin organization and nuclear microenvironments in cancer cellsShihua He, Katherine L Dunn, Paula S Espino, et al.
Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 15, 2023
Safety and immunogenicity of the live-attenuated varicella vaccine in pediatric solid organ transplant recipients: A systematic review and meta-analysisPierre-Philippe Piché-Renaud, Erika Yue Lee, Catherine Ji, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
Elife|April 10, 2014
Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cellsDorothy K Sojka, Beatrice Plougastel-Douglas, Liping Yang, et al.
Molecular Therapy. Nucleic Acids|January 16, 2025
Erratum: U1 Adaptor Oligonucleotides Targeting <i>BCL2</i> and <i>GRM1</i> Suppress Growth of Human Melanoma Xenografts <i>In Vivo</i>Rafal Goraczniak, Brian A Wall, Mark A Behlke, et al.
Molecular Therapy. Nucleic Acids|May 16, 2013
U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In VivoRafal Goraczniak, Brian A Wall, Mark A Behlke, et al.
ACS Synthetic Biology|November 18, 2025
CloneCoordinate: Open-Source Software for Collaborative DNA ConstructionEthan Jeon, Ziyang Shen, Santiago Christ, et al.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|September 5, 2020
Developing a pediatric ophthalmology telemedicine program in the COVID-19 crisisSaloni Kapoor, Amgad Eldib, Jamila Hiasat, et al.
Pageof 5